

Exceptional People
Committed to Providing
Exceptional Care



Ross Memorial Hospital is an active, 175-bed community general hospital providing quality acute and continuing care services to our community of over 80,000 residents. Located in the beautiful Kawarthas, the area boasts excellent educational and recreational facilities as well as a wide range of family and cultural amenities.

Emergency Medicine Physician

The Emergency Department has approximately 45,000 visits annually. A recently upgraded CT, new MRI, and an AFA are in place and are a few of the resources which support this department.

For a healthy lifestyle and a great career, join our caring team at Ross Memorial Hospital!

Please apply to:

Dr. A. E. Lauwers, VP Medical & Chief of Staff
Ross Memorial Hospital
10 Angeline Street North, Lindsay, ON K9V 4M8
E-mail: recruitment@rmh.org
Tel: 705.328.6115



ROSS MEMORIAL
HOSPITAL
Kawartha Lakes

www.rmh.org

CAEP Member Recruitment Program

When a colleague becomes a member of CAEP and names you a reference, CAEP will award you a \$100 voucher. This voucher can be used towards payment for any of the following:

- Your Membership Dues
- The Annual Conference
- CME in the SUN
- CME Roadshows



View the program details at CAEP.ca!

***CAEP is your Association.
Recruit a new member today!***



PART OF THE NOVARTIS COPD PORTFOLIO

Open up to a LAMA option in COPD

IMPROVED PATIENTS' QUALITY OF LIFE

(LS mean change in SGRQ total score vs. placebo, -3.32; $p < 0.001$)^{1,2†}



ONCE-DAILY ^{Pr} SEEBRI® BREEZHALER®

DEMONSTRATED 5-MINUTE ONSET AND 24-HOUR BRONCHODILATION

- FEV₁ improvement shown 5 minutes after first dose (0.093 L vs. placebo, $p < 0.001$, serial spirometry)^{1,3‡}
- Significantly greater LS mean FEV₁ vs. placebo demonstrated at all time points over 24 hours (LS mean FEV₁ [L] vs. placebo after first dose, $p < 0.001$; time points were 5 min, 15 min, 30 min, 1 hr, 2 hrs, 3 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, 23 hrs 15 min, 23 hrs 45 min)^{4§}

Indication & clinical use:

SEEBRI® BREEZHALER® is indicated as a long-term once-daily maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

- ▶ Not indicated for the relief of an acute deterioration of COPD
- ▶ Can be used at the recommended dose in elderly patients 65 years of age and older
- ▶ Should not be used in patients under 18 years of age

Relevant warnings and precautions:

- ▶ Not indicated for treatment of acute episodes of bronchospasm
- ▶ Not indicated for treatment of acutely deteriorating COPD
- ▶ Worsening of narrow-angle glaucoma
- ▶ Worsening of urinary retention
- ▶ In severe renal impairment, use only if the expected benefit outweighs the potential risk
- ▶ Paradoxical bronchospasm

For more information:

Please consult the Product Monograph at www.novartis.ca/asknovartispharma/download.htm?res=seebri%20breezhaler_scrip_e.pdf&resTitleId=665 for important information relating to adverse events, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling the Medical Information Department at 1-800-363-8883.

LAMA: long-acting muscarinic antagonist; COPD: chronic obstructive pulmonary disease; LS: least square; SGRQ: St. George's Respiratory Questionnaire, measures health-related quality of life in symptoms, activities and impact on daily life⁵; FEV₁: forced expiratory volume in 1 second.

† GLOW2: A 52-week, randomized, double-blind, placebo-controlled parallel-group study of 1,060 patients with COPD. Patients received either SEEBRI® BREEZHALER® (glycopyrronium 50 mcg o.d.; n=525), placebo (n=268), or open-label tiotropium (18 mcg o.d.; n=267) as an active control. Primary endpoint was 24-hour post-dose (trough) FEV₁ following 12 weeks of treatment.

‡ GLOW1: A 26-week, randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy, safety and tolerability of once-daily SEEBRI® BREEZHALER® (50 mcg) in patients with COPD (n=550); placebo (n=267).

§ LS mean FEV₁ (L) after first dose; SEEBRI® BREEZHALER® (n=169) vs. placebo (n=83), respectively: 5 min: 1.39 vs. 1.30; 15 min: 1.43 vs. 1.28; 30 min: 1.44 vs. 1.28; 1 hr: 1.47 vs. 1.28; 2 hrs: 1.53 vs. 1.34; 3 hrs: 1.53 vs. 1.35; 4 hrs: 1.52 vs. 1.35; 6 hrs: 1.48 vs. 1.33; 8 hrs: 1.47 vs. 1.33; 10 hrs: 1.47 vs. 1.32; 12 hrs: 1.45 vs. 1.31; 23 hrs 15 min: 1.37 vs. 1.27; 23 hrs 45 min: 1.39 vs. 1.31; $p < 0.001$ for all time points.

References: 1. SEEBRI® BREEZHALER® Product Monograph. Novartis Pharmaceuticals Canada Inc., December 3, 2013. 2. Kerwin E, Hébert J, Callagher N et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. *Eur Respir J* 2012;40:1106-14. 3. D'Urzo A, Fergusson GT, van Noord JA et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. *Respir Res* 2011;12(156):1-13. 4. Data on file. Novartis Pharmaceuticals Canada Inc. 5. Jones P. St. George's Respiratory Questionnaire Manual. Available from: www.healthstatus.sgu.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf. Accessed May 16, 2014.



Novartis Pharmaceuticals Canada Inc.
Dorval, Québec H9S 1A9
www.novartis.ca
☎ 514.631.6775 ☎ 514.631.1867

SEEBRI and BREEZHALER are registered trademarks.
Product Monograph available on request.
14SEED033E
© Novartis Pharmaceuticals Canada Inc. 2014



Once Daily
seebri®
breezhaler®
Glycopyrronium inhalation powder

